Donate Now
  • Research Ongoing
Mapping the epidemiology and the role of treatments in mental health complications in inflammatory arthritis (MATTERS)
matters-study-mary-de-vera
Scientific Study Title:
Mapping the epidemiology and the role of treatments in mental health complications in inflammatory arthritis (MATTERS)
Start Date:
  • 01/2019
End Date:
  • 12/2021
Research Category
Tags
Mary De Vera-Website Headshot-400x400
Mary De Vera
MSc, PhD, Associate Director of Training, Senior Scientist, Pharmacoepidemiology

Ready to Participate?

Life-changing arthritis research is only possible with your help!
Participate Now

Why do this research?

Reason For Research

Arthritis is a very painful condition that affects over 6 million Canadians. The goal of this research is to study mental health in people with arthritis. This is an understudied issue despite the complex relationship between arthritis and psychiatric conditions. A better understanding of mental health complications will help improve care for people with arthritis and bring awareness to the equal importance of mental health to physical health.

Methodology

Execution of Research

We will use “big data” in BC, which links all health data on doctor visits, hospitalizations, and prescriptions for the entire population of British Columbia. We will evaluate whether the number of people newly diagnosed with arthritis who also have depression and/or anxiety has increased over time. We will also evaluate the onset of depression and anxiety after diagnosis of arthritis, including when it occurs and associated factors. Finally, we will study how depression and anxiety are treated among people with arthritis and whether medications (biologics) for arthritis may reduce the risk of depression and anxiety.

Who is involved?

Involvement

Alyssa Howren, MSc, PhD Student at UBC Faculty of Pharmaceutical Sciences and Trainee at ARC

Eileen Davidson, Patient Partner, ARC Arthritis Patient Advisory Board

Antonio Avina-Zubieta, MD, PhD, Associate Professor at UBC’s Faculty of Medicine, Division of Rheumatology and Research Scientist at ARC

John Esdaile MD, MPH, Professor at UBC’s Faculty of Medicine, Division of Rheumatology and Scientific Director at ARC

Kam Shojania, MD, Clinical Professor and Head of UBC’s Faculty of Medicine, Division of Rheumatology

Deborah Da Costa, PhD, Associate Professor at McGill University’s Faculty of Medicine

Joseph H. Puyat, PhD, Assistant Professor at UBC’s School of Population and Public Health, Scientist at the Centre for Health Outcomes and Evaluation Sciences, and Scientist at the Mental Health Program at Providence Health Care

Related Research

Ozempic-PLS-Feature-Image-425x296-1

Are medications like Ozempic safe and effective for people with inflammatory arthritis and type 2 diabetes?

Read More
2026-Studies-to-Watch-Decision-Aid

Evaluating a Decision Aid for Tapering Biologic Medications in Rheumatoid Arthritis

Read More
arc_placeholder_new

What is the real risk of getting COVID-19, and how serious can it be, for British Columbians who are taking medications that affect their immune system?

Read More
Research_Inflammatory-Arthritis-from-Cancer-Immunotherapy_425x296

Inflammatory Arthritis from Cancer Immunotherapy: A Canada-Wide Study

Read More
Research-PLS_Making-Strength-Training-Easy-for-Arthritis_425x296

Making Strength Training Easy for People with Arthritis

Read More
Comparing-Risks-and-Benefits-of-Different-Treatments-for-Inflammatory-Arthritis_web

Comparing Risks and Benefits of Different Treatments for Inflammatory Arthritis

Read More